NCT07895056
A Study to Assess Adverse Events and Change in Disease Activity of Intravenous (IV) ABBV-706 in Combination With Tarlatamab and Atezolizumab in Adult Participants With Extensive Stage-Small Cell Lung Cancer
Track this trial
Free. We email you which fields changed when ClinicalTrials.gov updates this record.
Record History
All 1 version: 1 with changes below.
- Study First Submitted
Endpoints
Primary
Objective Response (OR) measured by overall response rate (ORR) Based on Blinded Independent Central Review (BICR) Assessment Per Response Evaluation Criteria in Solid Tumors (RECIST) Version 1.1
Timeframe: Up to Approximately 4 Years
Number of Participants with Adverse Events (AEs)
Timeframe: Up to Approximately 4 Years
Secondary (4)
Duration of Response (DoR) Based on BICR Per RECIST v1.1
Disease Control (DC) Based on BICR Per RECIST v1.1
Overall Survival (OS)
Progression-Free Survival (PFS) Based on BICR Per RECIST v1.1
Arms and interventions
ABBV-706 Dose A + Tarlatamab + AtezolizumabExperimental
Participants will receive ABBV-706 dose A in combination with atezolizumab and tarlatamab during the safety lead-in and dose expansion periods.
ABBV-706 Dose B + Tarlatamab + AtezolizumabExperimental
Participants will receive ABBV-706 dose B in combination with atezolizumab and tarlatamab during the safety lead-in and dose expansion periods.
Drugs: ABBV-706, Tarlatamab, Atezolizumab